NCI has issued two Requests for Applications and a Request for Proposals focused on COVID-19 serology and immunology.
The name of the session was a message in and of itself: “Racism and Racial Inequalities in Cancer Research.”
The proportion of racial and ethnic minority patients in NCI-funded clinical trials has nearly doubled over two decades—from 14% in 1999 to 25% in 2019, according to data from NCI's National Clinical Trials Network and the NCI Community Oncology Research Program.
People living in rural communities are often located far away from the major cancer centers that offer a full spectrum of treatments, including clinical trials.
Early in the War Against Cancer, when huge amounts of federal funds were suddenly funneled into cancer research, many scientists and clinicians working in other fields suddenly found it convenient—if not essential—to incorporate cancer into the title of their grant applications.
The American Cancer Society has raised $160 million so far this year, an astonishingly low number for an organization that historically has booked about half of its funds from walks, runs, and relays that take place in the spring and early summer.
The COVID-19 pandemic will likely cause at least 10,000 excess deaths from breast cancer and colorectal cancer over the next 10 years in the United States.
The Cancer Letter received five 2020 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists:
In the midst of the heavy burden COVID-19 has placed on the health care system, cancer remains relentless. The already difficult journey for cancer patients has become more uncertain as the ways we provide and access healthcare have changed to accommodate measures that protect both health care providers and cancer patients from COVID-19.
